61 related articles for article (PubMed ID: 34336697)
1. DHRS4-AS1 regulate gastric cancer apoptosis and cell proliferation by destabilizing DHX9 and inhibited the association between DHX9 and ILF3.
Xiao L; Zhang Y; Luo Q; Guo C; Chen Z; Lai C
Cancer Cell Int; 2023 Dec; 23(1):304. PubMed ID: 38041141
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Application Research of Individualized Conditional Reprogramming System to Guide Treatment of Gastric Cancer.
Zhao W; Liu K; Sun Z; Wang L; Liu B; Liu L; Qu X; Cao Z; Sun J; Chai J
Front Oncol; 2021; 11():709511. PubMed ID: 34336697
[TBL] [Abstract][Full Text] [Related]
4. Generation of stable PDX derived cell lines using conditional reprogramming.
Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM
Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548
[TBL] [Abstract][Full Text] [Related]
5. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
Cao J; Chan WC; Chow MSS
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Application of Conditional Reprogramming Culture System for Laryngeal and Hypopharyngeal Carcinoma.
Dong Y; Wang J; Ji W; Zheng M; Wang P; Liu L; Li S
Front Cell Dev Biol; 2021; 9():744969. PubMed ID: 34778255
[TBL] [Abstract][Full Text] [Related]
7. Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay.
Li Y; Guo D; Zhang Y; Wang L; Sun T; Li Z; Zhang X; Wang S; Chen Y; Wu A
Transl Oncol; 2021 Jan; 14(1):100935. PubMed ID: 33190042
[TBL] [Abstract][Full Text] [Related]
8. Conditional reprogramming: next generation cell culture.
Wu X; Wang S; Li M; Li J; Shen J; Zhao Y; Pang J; Wen Q; Chen M; Wei B; Kaboli PJ; Du F; Zhao Q; Cho CH; Wang Y; Xiao Z; Wu X
Acta Pharm Sin B; 2020 Aug; 10(8):1360-1381. PubMed ID: 32963937
[TBL] [Abstract][Full Text] [Related]
9. Conditional Reprogramming Inducing Clinical Cells Proliferation: New Research Tools in Tumor and Inflammatory-related Diseases.
Chai J; Han L; Zhang J; Han D; Zou L; Zhu Z; Zhao Y; Guo H
Curr Pharm Des; 2020; 26(22):2657-2660. PubMed ID: 32175833
[TBL] [Abstract][Full Text] [Related]
10. Conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between EGFR and MEK or CDK4/6 inhibitors.
Wang Y; Liao H; Zheng T; Wang J; Guo D; Lu Z; Li Z; Chen Y; Shen L; Zhang Y; Gao J
Am J Cancer Res; 2020; 10(1):249-262. PubMed ID: 32064165
[TBL] [Abstract][Full Text] [Related]
11. Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.
Palechor-Ceron N; Krawczyk E; Dakic A; Simic V; Yuan H; Blancato J; Wang W; Hubbard F; Zheng YL; Dan H; Strome S; Cullen K; Davidson B; Deeken JF; Choudhury S; Ahn PH; Agarwal S; Zhou X; Schlegel R; Furth PA; Pan CX; Liu X
Cells; 2019 Oct; 8(11):. PubMed ID: 31717887
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
